Cargando…
Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11b(high)/Gr1(high) myeloid cells
The anti-VEGF humanized antibody bevacizumab suppresses various malignancies, but tumors can acquire drug resistance. Preclinical studies suggest myeloid-derived suppressor cells (MDSCs) may be associated with tumor refractoriness to anti-VEGF treatment. Here we report a novel mechanism of tumor esc...
Autores principales: | Iwai, Toshiki, Harada, Yui, Saeki, Hiroshi, Oki, Eiji, Maehara, Yoshihiko, Yonemitsu, Yoshikazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915143/ https://www.ncbi.nlm.nih.gov/pubmed/29707135 http://dx.doi.org/10.18632/oncotarget.24811 |
Ejemplares similares
-
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104)
por: Satake, Hironaga, et al.
Publicado: (2016) -
The requirement of Mettl3-promoted MyoD mRNA maintenance in proliferative myoblasts for skeletal muscle differentiation
por: Kudou, Kensuke, et al.
Publicado: (2017) -
BubR1 Insufficiency Results in Decreased Macrophage Proliferation and Attenuated Atherogenesis in Apolipoprotein E‐Deficient Mice
por: Tanaka, Shinichi, et al.
Publicado: (2016) -
Mass-production of human dendritic cells in accordance with gmp for clinical studies
por: Harada, Yui, et al.
Publicado: (2015) -
High ubiquitin‐specific protease 44 expression induces DNA aneuploidy and provides independent prognostic information in gastric cancer
por: Nishimura, Sho, et al.
Publicado: (2017)